Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

ABSTRACT: Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

PROVIDER: PRJNA1051129 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27180800_1.fastq.gz	Fastqsanger.gz
	SRR27180800_2.fastq.gz	Fastqsanger.gz
	SRR27180801_1.fastq.gz	Fastqsanger.gz
	SRR27180801_2.fastq.gz	Fastqsanger.gz
	SRR27180802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 58

Similar Datasets

Differential mRNA expression analysis of H358 and AsPC-1 cell xenograft mouse model after MCB-22-294 treatment

Project description:The mechanism of action of a pan-Kras inhibitor MCB-22-294 remains unknown. We determined gene expression profiling in H358 and AsPC-1 cell line xenograft mouse models after MCB-22-294 treatment using RNA-seq analysis.

2024-02-22 | GSE249914 | GEO

Label-free quantitative proteomics analysis of ASPC-1 and H358

Project description:ASPC-1 and H358 cells were collected after being treated with 100nM MCB-36 for 24h. Cells were lysed in UA solution followed by mechanical grinding at a frequency of 60 Hz at 4°C for 60 min. The lysate was centrifuged and the supernatant was collected as a whole extract. Samples were then digested using the filter-aided sample preparation method. Liquid chromatography tandem MS (LC-MS/MS) analysis was performed by coupling a nanoLC column to an Orbitrap Q-Exactive Plus mass spectrometer.

2023-11-30 | PXD047389 |

Oscheius sp. MCB isolate:MCB

Project description:Oscheius sp. MCB isolate:MCB Genome sequencing and assembly

| PRJNA275059 | ENA

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [bulk RNA-seq]

Project description:KRAS is the most frequently mutated oncogene in human cancers, but to date, only KRASG12C inhibitors have been FDA-approved. Small-molecule inhibitors that target other more prevalent KRAS mutations are in urgent clinical need. Here, we report a highly potent pan-KRAS inhibitor, MCB-294, that selectively targets KRAS, but not HRAS or NRAS. Molecular profiling studies show that MCB-294 binds to and inhibits several KRAS mutants, including G12D, G12C, G12V, thereby disabling KRAS oncogenic signaling. MCB-294 is well tolerated in mice and exhibits remarkable therapeutic efficacy against the growth of a comprehensive range of KRAS-driven cancer cell lines, patient-derived organoids, and tumor xenografts and prolongs mouse survival. By employing an MCB-294 derivative as the KRAS binder, we further identify a VHL-based pan-KRAS degrader, MCB-36, that efficiently degrades KRAS in vitro and in vivo through the ubiquitin-proteasome system. Importantly, MCB-294 and MCB-36 not only effectively kill KRASG12C inhibitor-resistant cells, but also reshape the tumor microenvironment by boosting T cell-mediated anti-tumor immunity. Taken together, our findings demonstrate a successful and feasible strategy for targeting pan-KRAS to impair multifaceted features of KRAS-driven cancers.

2024-07-30 | GSE273116 | GEO

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [CD45+ scRNA-seq]

2024-08-03 | GSE273301 | GEO

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers [scRNA-seq]

2024-08-03 | GSE273300 | GEO

A Steroid Receptor Coactivator Stimulator (MCB-613) Prevents Adverse Remodeling After Myocardial Infarction

Project description:A Steroid Receptor Coactivator Stimulator (MCB-613) Prevents Adverse Remodeling After Myocardial Infarction

2020-09-06 | GSE157542 | GEO

Sequencing of AsPC-1 cells with CYP3A5 expression modulation

Project description:Purpose: To understand the transcriptome-wide effect of CYP3A5 knockdown or over-expression in AsPC-1 cells

2024-04-17 | GSE149000 | GEO

Serratia marcescens strain:MCB